Comparing long-course chemoradiation versus short-course radiation plus CAPOX, a PD-1 blocker (serplulimab), and celecoxib for locally advanced rectal cancer
Official title: A Randomized Phase II Study of Long-term Chemoradiotherapy or Short-term Radiotherapy Combined With CAPOX, PD-1 Monoclonal Antibody and COX-2 Inhibitors in MSS Type Locally Advanced Rectal Cancer
Run by Fudan University · NCT07154316 · Data updated 2026-11-12
This trial will test whether adding CAPOX, the PD-1 drug serplulimab, and celecoxib to short-course radiotherapy works better than standard long-course chemoradiation for adults with MSS locally advanced rectal cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 138 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, serplulimab |
| Locations | 5 sites (Fuzhou, Fujian and 4 other locations) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | August 1, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | September 4, 2025 |
| Trial ID | NCT07154316 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults age 18–75 with pathologically confirmed MSS/pMMR locally advanced rectal adenocarcinoma (T3-4 and/or N+, tumor ≤10 cm from anal verge), no distant metastasis, KPS ≥70, and no prior chemotherapy or immunotherapy.
✕Probably not a fit
Patients with MSI-high/dMMR tumors, distant metastases, prior systemic therapy, poor performance status, pregnancy, or serious uncontrolled comorbidities are unlikely to benefit or are ineligible for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized phase II trial enrolls adults with microsatellite-stable (MSS) locally advanced rectal adenocarcinoma to compare standard long-course chemoradiotherapy (50 Gy in 25 fractions with capecitabine) against short-course radiotherapy (25 Gy in 5 fractions) followed by CAPOX (capecitabine plus oxaliplatin), the PD-1 inhibitor serplulimab, and the COX-2 inhibitor celecoxib. The primary endpoint is combined complete response rate (pathologic complete response plus clinical complete response), with secondary endpoints including anal-preservation rate and three-year survival outcomes. The protocol also includes correlative studies to explore how the triple regimen alters the tumor microenvironment and immune response. Participants must be treatment-naïve for chemotherapy and immunotherapy and have tumors located ≤10 cm from the anal verge.
Why it matters
Potential benefit: If successful, the combination approach could raise complete remission rates and increase the chance of preserving the anus while reducing recurrence.
How similar studies have gone: Short-course radiotherapy combined with chemotherapy and PD-1 blockade has shown encouraging early signals in rectal cancer, but adding a COX-2 inhibitor like celecoxib is a novel component that remains exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-75 years, regardless of gender. * Pathologically confirmed rectal adenocarcinoma. * Tumor located ≤10 cm from the anal verge. * Baseline stage T3-4 and/or N+ (locally advanced disease). * No evidence of distant metastasis. * Microsatellite stability (MSS) or proficient mismatch repair (pMMR). * Karnofsky Performance Status (KPS) ≥70. * No prior chemotherapy or any other anticancer therapy before enrollment. * No prior immunotherapy. * Able to comply with study protocol requirements throughout the study period. * Signed written informed consent obtained prior to study participation. Exclusion Criteria: * Pregnant or lactating women. * Individuals with a history of other malignant diseases within the past 5 years, excluding cured skin cancer and cervical carcinoma in situ. * Individuals with a history of uncontrolled epilepsy, central nervous system diseases, or mental disorders, where the clinical severity (as judged by the investigator) may impair the ability to sign the informed consent form or affect compliance with oral medication. * Clinically significant (i.e., active) heart disease, including symptomatic coronary heart disease, congestive heart failure of New York Heart Association (NYHA) class II or worse, severe arrhythmias requiring pharmacological intervention, or a history of myocardial infarction within the past 12 months. * Individuals requiring immunosuppressive therapy for organ transplantation and those on long-term corticosteroid therapy. * Individuals with autoimmune diseases. * Individuals with severe, uncontrolled, recurrent infections or other severe, uncontrolled concurrent diseases. * Baseline blood routine and biochemical parameters not meeting the following criteria: hemoglobin ≥90 g/L; absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelets ≥100×10⁹/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× upper limit of normal (ULN); alkaline phosphatase (ALP) ≤2.5×ULN; serum total bilirubin \<1.5×ULN; serum creatinine \<1×ULN; serum albumin ≥30 g/L. * Individuals with known dihydropyrimidine dehydrogenase (DPD) deficiency. Individuals with a history of hypersensitivity to any component of the study medications.
Where it's running
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China Recruiting -
Anyang Tumor Hospital
Anyang, Henan, China Recruiting -
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China Recruiting -
Yunnan Cancer Hospital
Kunming, China Recruiting -
Fudan University Shanghai Cancer Center
Shanghai, China Recruiting
Study contacts
- Study coordinator: Dawei Li
- Email: li_dawei@fudan.edu.cn
- Phone: +86-021-64175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.